The immunomodulatory capacity of mesenchymal stem cells (MSCs) is critical for their use in therapeutic applications. MSC response to specific inflammatory cues allows them to switch between a proinflammatory (MSC1) or anti-inflammatory (MSC2) phenotype. Regulatory mechanisms controlling this switch remain to be defined. One characteristic feature of MSC2 is their ability to respond to IFNc with induction of indoleamine 2,3-dioxygenase (IDO), representing the key immunoregulatory molecule released by human MSC. Here, we show that STAT1 and PI3Ka pathways interplay regulates IFNc-induced IDO production in MSC. Chemical phosphoinositide 3-kinase (PI3K) pan-inhibition, PI3Ka-specific inhibition or shRNA knockdown diminished IFNc-induced IDO production. This effect involved PI3Ka-mediated upregulation of STAT1 protein levels and phosphorylation at Ser727. Overexpression of STAT1 or of a constitutively active PI3Ka mutant failed to induce basal IDO production, but shifted MSC into an MSC2-like phenotype by strongly enhancing IDO production in response to IFNc as compared to controls. STAT1 overexpression strongly enhanced MSC-mediated T-cell suppression. The same effect could be induced using short-term pretreatment of MSC with a chemical inhibitor of the counter player of PI3K, phosphatase and tensin homolog. Finally, downregulation of STAT1 abrogated the immunosuppressive capacity of MSC. Our results for the first time identify critical upstream signals for the induced production of IDO in MSCs that could be manipulated therapeutically to enhance their immunosuppressive phenotype.
INTRODUCTION
Due to their potent immunomodulatory function, mesenchymal stem cell (MSC) have become the focus of attention as a promising cell therapy for the treatment of various refractory immune-mediated diseases in humans [1] [2] [3] [4] . Similar to macrophage polarization into the proinflammatory M1 or antiinflammatory M2 phenotype, MSCs are sensors of inflammation and are able to adopt a proinflammatory (MSC1) or anti-inflammatory (MSC2) phenotype depending on inflammatory environmental cues and their interaction with components of the innate and/or adaptive immune system, both in vitro and in vivo [5, 6] . The proinflammatory MSC1 phenotype appears to aid in establishing a proper early inflammatory response, while the immunesuppressive MSC2 phenotype aids at later stages to control or suppress inflammatory Tcell responses, a fact that has been exploited for therapeutic applications [5, 6] . The regulatory mechanisms that control the phenotypic switch between MSC1 and MSC2 phenotypes remain to be fully explored.
A key feature of MSC2 is that they respond to the proinflammatory cytokine IFNc with production and release of indoleamine 2,3-dioxygenase (IDO), the key immunosuppressive molecule in human MSC [7] [8] [9] . IFNc is the key inflammatory cytokine released by activated macrophages and activated T cells in inflammatory conditions. IDO exerts its immunosuppressive function (a) by increasing the catabolism of tryptophan and the production of toxic tryptophan metabolites (kynurenines), resulting in cell cycle arrest and apoptosis of T cells [10] , and (b) by creating a milieu that favors the production of Tregs, specialized T helper cells that suppress activated T cells. MSCs pretreated with IFNc are much more potent in the treatment of inflammatory diseases [11, 12] . Consequently, identification of conditions and key regulatory components that control the immunophenotype of MSCs and their response to IFNc could potentially be used to enhance therapeutic applications of MSCs [13] . Unfortunately, signaling components that mediate the phenotypic switch from MSC1 to MSC2 or that regulate IFNc-induced IDO production in MSC2 are so far largely unknown [5] .
The major signaling pathway activated by IFNc receptor involves the sequential activation of Janus kinase (Jak) and signal transducer and activator of transcription (STAT) proteins. However, cell type-specific responses to IFNc are complex and can involve differential activation of STAT isoforms [14] . Furthermore, IFNc-induced activation of kinases such as phosphoinositide 3-kinase (PI3K) has been reported [15] [16] [17] [18] . Whether these signaling events and in particular PI3K are connected to IFNc-induced IDO production and/or act in concert to help establish or enhance the MSC2 phenotype is unknown.
In this report, we show that IFNc-induced IDO production in MSC depends on the interplay of PI3Ka and STAT1 pathways. PI3Ka pathway activation was required for full IFNcmediated STAT1 activation and mediated phosphorylation of STAT1 at S727. Overexpression of STAT1 or of a constitutively active PI3Ka mutant shifted MSCs into a MSC2-like phenotype in that it strongly potentiated IFNc-mediated IDO production and, in the case of STAT1 overexpression, also enhanced T-cell suppression by MSCs. A similar effect could be obtained by short pretreatment of MSC with a chemical inhibitor of phosphatase and tensin homolog (PTEN), which normally inhibits PI3K pathway. Our findings identify novel key signaling components that control the MSC2 immunosuppressive phenotype by regulating IFNc-induced IDO production and offer a potential strategy to enhance the immunomodulatory function of MSC in the treatment of diseases.
MATERIALS AND METHODS

Reagents
Inhibitors used were: LY294002 (PI3K inhibitor) and Rapamycin (Sigma-Aldrich, St. Louis, MO); STAT3 inhibitor IV (STAT3 inhibitor) (Millipore, Temecula CA); Torin1 inhibitor (Tocris, Bristol, U.K.). PIK-75 (PI3Ka inhibitor), TGX-221 (PI3Kb inhibitor) and CAL-101 (PI3Kd inhibitor) (Selleckchem, Houston, TX), SF1670 (PTEN inhibitor), and anti-human CD119 (anti-IFNGR1) (Biolegend, San Diego, CA). The following primary antibodies were used: rabbit monoclonal antibody against phospho-STAT1 (Tyr701), STAT1, STAT3, phospho-Akt (Thr308), and pan-Akt (Cell signaling, Technology , Beverly, MA); mouse monoclonal antibody against phospho-STAT1 (Ser727), indoleamine 2, 3-dioxygenase (Millipore, Temecula CA), Ki67 (Vector laboratories (Burlingame, CA)), and b actin (Sigma-Aldrich, St. Louis, MO). The STAT1 and constitutively active PI3Ka (CA-PI3Ka) plasmids were from Addgene (Cambridge, MA) (#12301 and #12524). Recombinant human IFNc was from Peprotech , Inc. (Rocky Hill, NJ).
CB-MSC Culture and Treatments
CB-MSCs were obtained through a collaboration with Viacord LLC, a PerkinElmer company, and cultured in Dulbecco's modified Eagle's medium (DMEM) (Lonza, Walkersville, MD) supplemented with 20% fetal bovine serum (FBS) (Gemini BioProducts, Sacramento, MA), 1% penicillin/streptomycin (Lonza, Walkersville, MD), and 1% L-Glutamine (Lonza, Walkersville, MD). The cells were incubated at 37 C and 5% CO 2 and their medium was replaced every 3-4 days. When the cells reached 70%-80% confluence MSCs were trypsinized (0.25% Trypsin-EDTA 13; Life Technologies, Grand Island, NY) and passaged. For in vitro experiments, CB-MSCs were plated in six-well plates at a density of 100 3 10 3 cells/well and incubated overnight. The next day cells were either pretreated with inhibitor or DMSO (vehicle) for 1 hour and then either stimulated with IFNc (40 ng/ml) or left unstimulated and incubated at 37 C and 5% CO 2 for 24 hours unless otherwise specified. Supernatant and cell lysates were collected for cytokine analysis and Western blots respectively. For studies assessing the phosphorylation state of molecules, incubation with serumfree medium was used to reduce background.
CB-MSC Characterization and Differentiation
We used cultured CB-MSC at passages 4-8 in all experiments. Cells were surface stained for flow cytometry using a panel of anti-human antibodies against CD73, CD105, CD34, CD45, CD14, HLA-ABC, CD49c, CD49e, HLA-DR (BD Pharmingen, San Diego, CA), CD49d, and CD49f (eBioscience, San Diego, CA) (Supporting Information Fig. S1A ). For differentiation into osteoblasts, subconfluent CB-MSCs were cultured in media supplemented with 0.1 mM dexamethasone, 50 mM ascorbate-2-phosphate, and 10 mM b-glycerophosphate (Sigma-Aldrich, St. Louis, MO) for 21 days. Osteogenesis was demonstrated by quantitative Ca 21 determination using Calcium (CPC) Liquicolor Kit (Stanbio Laboratory, Boerne, TX) according to the manufacturer's instructions (Supporting Information Fig. S1B ). For adipogenic differentiation, confluent cells were cultured in Complete Medium supplemented with 1 mM dexamethasone, 10 mg/ml insulin, 0.5 mM IBMX, and 100 mM indomethacin (all from Sigma-Aldrich, St. Louis, MO). Adipogenic differentiation was confirmed by staining with AdipoRed (Lonza, Walkersville, MD) (Supporting Information Fig. S1B ). For chondrogenic differentiation, confluent cells were cultured in low glucose-DMEM supplemented with 2 mM L-glutamine, 1% antibiotic-antimycotic, 1% ITS-Premix (Invitrogen, Carlsbad, CA), 100 nM dexamethasone, 50 mM ascorbate-2-phosphate, and 10 ng/ml of TGF-b1 for 21 days and chondrogenesis was demonstrated by staining with toluidine blue (Spectrum Chemicals, Gardena, CA) (Supporting Information Fig. S1B ). The ability of CB-MSC to dosedependently suppress the proliferation of CD4 T lymphocytes as well as the potentiation of their immunosuppressive function by IFNc was confirmed using an in vitro suppression assay (described below) (Supporting Information Fig. S1C ).
Transfections and Viral Transduction
Virus production and transduction were performed as previously described [19] . Briefly, HEK293T cells were transfected with 1 lg lentiviral CA-PI3Ka plasmid, 0.9 lg of VSVG, and 0.1 lg deltaPVR using Fugene6 (Roche, Mannheim, Germany). Viral supernatant was used to infect 50% confluent CB-MSC cultures in the presence of 4 mg/ml Polybrene. For CB-MSC transfection experiments, Attractene (QIAGEN) was used to transfect 50% confluent cells according to manufacturer's instructions. washed three times, and then used in the T-cell proliferation assay. The anti-CD3/CD28 proliferation assay was performed as previously described [20] . Isolated peripheral blood mononuclear cells (PBMCs) were reconstituted (at 100,000-200,000 cells/well in a 96-well-plate) with RPMI complete medium (RPMI 1640, supplemented with 10% FBS, 1% penicillinstreptomycin, and 1% L-glutamine), stimulated to proliferate with anti-CD3/CD28 antibodies (6 lg/ml) (eBioscience, San Diego, CA) and cocultured with irradiated (3,000 rad) CB-MSC for 3 days. CD4 T lymphocyte proliferation was measured by carboxyfluorescein succinimidyl ester (CFSE) incorporation (CellTrace CFSE, Molecular Probes, Invitrogen, Carlsbad, CA) as previously described [20] . In other instances, lymphocyte proliferation was measured by radioactive thymidine incorporation in PBMC. For this, cells in the above-described assay were pulse-treated with tritiated thymidine (PerkinElmer, Waltham, MA) on the third day for 8-16 hours and thymidine incorporations were later analyzed with a liquid scintillation counter.
Luminex Assay
To assess cytokine production in culture supernatant samples, a 21-plex cytokine kit (Millipore, Temecula CA) was used according to the manufacturer's instructions.
Western Blot Analysis
CB-MSCs were lysed in ice-cold lysis buffer (RIPA buffer, protease inhibitor, phosphatase inhibitor cocktail 2 and 3 all purchased from Sigma-Aldrich, St. Louis, MO) on ice. Protein quantification of cell lysates was completed using the Bradford (Bio-Rad, Hercules, CA) assay. Equal amounts of protein were separated by 4%-10% SDS-PAGE and transferred to a Nitrocellulose membrane. The membranes were blocked with 5% non-fat milk in TBS-Tween solution (0.05% Tween 20 in Tris buffered saline) and then incubated overnight at 4 C with primary antibodies. The blots were then washed with TBS-Tween solution and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies (1:500) for 2 hours at room temperature, washed again with TBS-tween, and then developed with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Waltham, MA). siRNA Knockdown PI3Ka (P110a), STAT1, and STAT3 knockdown were performed using validated small interfering RNAs (siRNA) (Ambion, Austin, TX). A nontargeting siRNA was used as a control. CB-MSCs were transfected with siRNA (50 nM) using RNA iMAX Lipofectamine (Invitrogen, Carlsbad, CA) according to manufacturer instructions. After 48 hours of siRNA addition, the cells were used for evaluation of knockdown efficiency, for induction of IDO by IFNc, and for evaluation of their suppressive effect in the proliferation assay. Knockdown efficiency for the corresponding proteins was evaluated by Western blot analysis.
Real-Time PCR and Gene Array Expression
Statistical Analysis
Data were expressed as the mean 6 SEM. Student's t test was used for comparison of results and p < .05 was considered as significant.
RESULTS
IDO Induction by IFNc in CB-MSC
We used cord blood-derived human MSC (CB-MSC; collaboration with Viacord LLC) for all our experiments. CB-MSCs were characterized as described in Materials and Methods (Supporting Information Fig. S1 ). Real-time PCR analysis of RNA extracted from na€ ıve CB-MSC revealed no baseline expression of IDO transcripts. IDO transcripts could be detected as soon as 2 hours post-IFNc stimulation, and increased for 24 hours poststimulation (Fig. 1A) . On the protein level, IDO could be detected as early as 8 hours poststimulation (not shown). To 
PI3Ka Is Required for IFNc-Induced IDO Production
The activation of several kinases, including PI3K, has been implicated in the cellular effects of IFNc largely based on chemical inhibitor studies. PI3Ks are increasingly recognized for their role in the regulation of multiple key cellular functions [21] [22] [23] and are divided into three classes. Class I PI3Ks are subdivided into class IA (PI3Ka, PI3Kb, and PI3Kd) and class IB (PI3Kc). Tyrosine kinase-associated receptors such as the cytokine receptors [24, 25] , including the IFNc receptor, activate class IA kinases; signals derived from G proteincoupled receptors (GPCRs) are mediated by the class IB kinase. Activation of PI3K results in downstream activation of Akt kinase and the generation of phosphatidylinositol products, which act as second messengers regulating cell responses [14, 26] .
Treatment of CB-MSC with the pan class I PI3K inhibitor LY294002 [27] abolished IFNc-induced IDO production ( Fig.  2A) and activation of Akt (Supporting Information Fig. S2A , S2B). We next examined the expression of PI3K subunits in CB-MSC. Real-time polymerase chain reaction analysis of RNA extracted from CB-MSC detected significant mRNA levels of the PI3K catalytic subunits p110a, b, and d, but failed to detect any p110c transcripts (data not shown). p110c transcripts remained undetectable after 24 hours IFNc stimulation (data not shown). Expression of p110a, b, and d subunits (but not of P110c) on the protein level was confirmed by SDS-PAGE (Fig. 2B) . On the protein level, IFNc induced only small effects on the expression level of PI3K subunits as compared to control treated cells. PI3Kalpha was slightly increased and PI3Kbeta and delta were moderately decreased after IFNc (Fig. 2B) .
To determine the role of the different PI3K catalytic subunits in the regulation of IDO, we first used subunit-specific inhibitors that target the p110a (PIK-75), p110b (TGX-221), and p110d (CAL-101) subunits. Only inhibition of the p110a subunit abrogated the IFNc-induced upregulation of IDO (Fig.  2C) . Consistent with this, specific knockdown of the P110a subunit by RNA interference (Fig. 2D ) confirmed its role in mediating the induction of IDO expression (Fig. 2E ).
PI3Ka Activity Is Required for Full STAT1 Activation
IFNc is known to regulate many of its downstream effector functions through the activation of STAT1 [14] . However, whether STAT proteins have a role in regulating IDO expression in MSC is unknown. In order to assess the role of STAT1 in the regulation of IDO, we used RNA interference to knockdown STAT1 or STAT3 (Supporting Information Fig. S2C ). Only STAT1 knockdown resulted in a strong reduction of IDO upregulation after IFNc stimulation (Fig. 3A) .
To further examine STAT1 activation, we examined the phosphorylation state of STAT1. Phosphorylation of STAT1 on Tyrosine 701 (Y701) is required for its translocation to the nucleus where it activates the transcription of IFNc target genes [14] , among them STAT1 itself. Consistent with this, gene array data of CB-MSCs stimulated with IFNc for 24 hours showed significant upregulation of STAT1 (Supporting Information Table S1 ). For full biological activity, STAT1 also needs to be phosphorylated at serine 727 (S727). IFNc stimulation indeed caused rapid phosphorylation of STAT1 within 30 minutes on both Y701 and S727 residues in CB-MSC (Fig. 3B) ; both phosphorylation events could be blocked by anti-IFNGR1 antibody. Since both, STAT1 and PI3Ka activity were necessary for IFNc-induced IDO production, we examined whether PI3Ka activity is required for phosphorylation and activation of STAT1. Short-term incubations with a PI3Ka specific inhibitor (PIK-75) blocked S727 phosphorylation, but not the phosphorylation of Y701 (Fig. 3B) . There was in fact a small increase of pY701-STAT1. We detected at least two STAT1 isoforms present in CB-MSC (visible dependent on SDS-PAGE gel percentage used and exposure time of the Western blot) and two alternatively spliced isoforms of STAT1 have indeed been described [28] . Both STAT1 isoforms showed increased phosphorylation of Y701 in response to IFNc, but the lower molecular weight isoform appeared to be the predominantly phosphorylated isoform. In the presence of the PI3Ka inhibitor PIK-75, the overall increase in the detected Y701 phosphorylation was mostly conferred by an increase in phosphorylation of the higher molecular weight isoform. We cannot fully explain this effect, but it is possible that this represents an unspecific effect of the inhibitor, as we do not see this effect in the presence of PI3Ka knockdown. PI3Ka knockdown significantly reduced STAT1 expression levels induced by 24 hours treatment with IFNc as compared to controls (Fig. 3C) . Taking downregulation of STAT1 into account, phosphorylation on Y701 did not change significantly, but S727 phosphorylation was strongly reduced (Fig. 3C) . These findings suggest that PI3K also regulates STAT1 transcription or protein stability.
Our results hence identify PI3Ka-mediated STAT1 phosphorylation as an essential cosignal for IFNc induced STAT1 expression and in particular for IDO induction. PI3Ka lies downstream of the IFNc receptor but upstream of STAT1 and appears to have a key dual role in IFNc signaling in MSC in that it is required for STAT1 expression and also for its activation.
Constitutively Active PI3Ka Overexpression or STAT1 Overexpression Enhances IFNc Induced STAT1 Activity and IDO Production
We next examined whether genetic manipulation of STAT1 or PI3Ka could be used to modulate STAT1 activity with the goal to enhance or block the immunosuppressive activity of CB-MSC by enhancing or blocking IDO production. Overexpression of a constitutively active PI3Ka mutant (CA-PI3Ka) did not raise basal IDO production, but strongly enhanced IFNc induced IDO production by 230% over control (Fig. 4A ). This increase in IDO production coincided with a slight enhancement of IFNc stimulated STAT1 phosphorylation at S727 and Y701 (Fig. 4A) . Overexpression of CA-PI3Ka raised basal phosphorylation of S727 only to a small degree, while basal Y701 activity was unchanged and remained undetectable as compared to vector control (Fig. 4A) . This latter result likely suggests that PI3Ka does not directly phosphorylate STAT1 but acts as an intermediate in IFNc-mediated signaling to STAT1 (also see Discussion). In addition, these results confirm that Y701 is likely not a target of PI3Ka (see above and Fig. 2 ).
Similar to CA-PI3Ka, STAT1 overexpression enhanced IDO production (by approximately 380% over control) only in the presence of IFNc (Fig. 4B) . Interestingly, basal phosphorylation of STAT1 at S727 was greatly enhanced by overexpression of STAT1 (Fig. 4B) , while basal Y701 phosphorylation was only slightly increased. Since IFNc was still required to induce IDO production, we conclude that STAT1 activation by S727 phosphorylation alone is not sufficient to raise IDO production. 
STAT1 and PI3Ka Modulate CB-MSC-Mediated T-Cell Suppression
CB-MSCs inhibit T lymphocyte proliferation in a dosedependent manner (Supporting Information Fig. S1C ) and we have used CB-MSC at "high-dose" and "low-dose" in our assays of modified CB-MSC to tease out the effect of our manipulations in T-cell suppression assays (Fig. 5 ). For these assays, CB-MSCs were cocultured with PBMCs pretreated with activating anti-CD3/CD28 antibodies (positive control). Control siRNA transfected CB-MSCs used at high-dose were able to suppress T-cell proliferation. However, CB-MSC with silenced STAT1, but not with silenced STAT3, completely lost their ability to suppress T-cell proliferation ( Fig. 5A ; high-dose CB-MSC), consistent with the strong inhibitory effect of STAT1 knockdown on IDO production (Fig. 3A) . In addition, highdose CB-MSC with silenced PI3Ka showed reduced T-cell suppressive activity as compared to control siRNA transfected cells ( Fig. 5B ; High dose CB-MSC), consistent with the requirement of PI3K pathway activation for full STAT1 activation in the induction of IDO (Figs. 3, 4) . When CB-MSCs were used at low-dose, we detected only a very small to no effect on T-cell proliferation ( Fig. 5C ; lowdose MSC, compare positive control with control vehicle treated CB-MSC). Under low-dose conditions control CB-MSC required exogenous IFNc stimulation to be able to suppress Tcell proliferation. However, overexpression of STAT1 in unstimulated CB-MSC rendered these cells as effective in suppressing T-cell proliferation as control cells treated with exogenous IFNc. In fact, in the presence of STAT1 overexpression, exogenous IFNc was unable to increase T-cell suppression of modified CB-MSC further (Fig. 5E, low-dose MSC) . However, the effect of STAT1 overexpression on T-cell suppression is by no means independent of IFNc. This effect is instead likely owed to the much stronger IDO production of these cells in response to IFNc known to be physiologically released by activated T cells in this assay (Supporting Information Fig. S2D ). Overexpression of constitutively active PI3Ka alone did not enhance IDO production by CB-MSC and did not render their T-cell suppression activity independent of exogenous IFNc as in the case of overexpressed STAT1 (data not shown). This confirms the notion that PI3K pathway activation is necessary for full STAT1 activation in CB-MSC but not sufficient to induce their IDO production and T-cell suppression.
Inhibition of PTEN, the Counter Player of PI3K, Enhances CB-MSC-Mediated T-Cell Suppression
Given that genetically modified CB-MSC might represent a general challenge for safety in therapeutic applications, and in particular, given that the overexpression of constitutively active PI3K increases proliferation of CB-MSC (Supporting Information Fig. S2E ) and thereby potentially increases risk of malignant transformation, we explored other options of CB-MSC modulation without genetic modification. Another possible approach to modulation of the PI3K pathway in CB-MSC is the inhibition of the PI3K counter-player, the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) [29] . PTEN inhibition would be expected to enhance PI3K pathway activation and thereby IDO production and T-cell suppression. Therefore, we used a chemical inhibitor of PTEN, SF1670, which did not increase the proliferation of CB-MSC (Supporting Information Fig. S2E ). Short (30 minutes) and long (24 hours) term effects of the PTEN inhibitor SF1670 on STAT1 phosphorylation and IDO production were examined. Pretreatment of CB-MSC with SF1670 enhanced the basal as well as the IFNc-induced S727 STAT1 phosphorylation, examined 30 minutes after IFNc stimulation (Fig. 6A, left panels) . PTEN inhibitor however did not affect the acute phosphorylation of STAT1 at Y701, again confirming that PI3K pathway activation is required for S727 phosphorylation but not Y701 phosphorylation (Figs. 3, 4) . At the 24 hours time point, there are only marginal differences in STAT1 phosphorylation levels between SF1670 treated and nontreated samples (Fig. 6A, right panels) . Similarly to CA-PI3Ka overexpression, SF1670 did not affect basal IDO production in MSC. However, after 24 hours of IFNc stimulation, the production of IDO is approximately twofold higher in the SF1670-treated samples (Fig. 6B, right panels) .
As expected, SF1670 also increased IFNc-induced, but not basal, mRNA expression levels of STAT1 and IDO, as tested by qPCR (Supporting Information Fig. S2F ). Interestingly, shortterm pretreatment of CB-MSC with the inhibitor was sufficient to prime CB-MSC for enhanced T-cell suppression, even in the absence of exogenous IFNc. However, IFNc was still able to potentiate the effect of the inhibitor on T-cell suppression (Fig. 6B, 6C ). Taken together, these results show that it might be feasible to enhance the immunosuppressive activity of CB-MSC with chemical short-term modifications only, possibly prior to introducing CB-MSC into the patient, offering a strong advantage over stable genetic modification. In summary, our results suggest that the interplay of STAT1 and PI3Ka plays a key role in regulating the immunophenotype of MSC. 
DISCUSSION
MSC immunomodulatory properties hold great promise for the treatment of refractory immune-mediated diseases [1, 30] . In addition, their safety profile, easy isolation, and capability for fast expansion ex vivo contribute to their clinical therapeutic potential [1, [31] [32] [33] . However, the signaling pathways and regulatory components that orchestrate the phenotypic switch of MSC from proinflammatory (MSC1) to antiinflammatory (MSC2) are unknown. In this study, we have focused on IDO induction as the key IFNc-induced immunoregulatory molecule in human MSC2 [5, 6] . The identification of key signaling molecules that regulate the dynamic switch between MSC immune phenotypes is expected to lead to the development of more potent therapeutic approaches using MSC in the therapy of immune-mediated diseases. Our data reveal a critical role for the interplay between STAT1 and the PI3K pathway in IFNc-induced IDO production and MSC immune phenotype regulation. Amongst various subtypes of PI3Ks, we identify PI3Ka as a major novel regulator of IFNc induced IDO expression upstream of STAT1. Furthermore, our work adds important detail to recent reports by others that also linked STAT1 activation to IFNc-induced IDO expression in MSC and non-MSC cell types [13, [34] [35] [36] . We show that full IFNc-mediated STAT1 activation, as assessed by phosphorylation of at least two critical STAT1 residues, S727 and Y701, depends on IFNc-induced PI3Ka pathway activation. Activation of the PI3K pathway and of STAT1 is necessary for IFNc induced IDO production, as shown by blocked IDO production in PI3Ka or STAT1 knockdown cells. Moreover, inhibition of the PI3K counter-player PTEN potentiated S727-STAT1 phosphorylation, IFNc-induced IDO production and T-cell suppression. Notably, PI3K pathway activation or activation of STAT1 was not sufficient for IDO induction, as PTEN inhibition or overexpression of either CA-PI3Ka or STAT1 did not yield basal IDO production without the addition of IFNc. As noted in Results, overexpression of CAPI3Ka raised basal S727 phosphorylation to only a small degree and left basal Y701 activity (Fig. 4A) . It is therefore likely that PI3Ka does not directly phosphorylate STAT1 but acts via an intermediate which itself depends on IFNc-mediated signaling to STAT1. However, all three modifications (STAT1 or PI3K overexpression; PTEN inhibition) that led to enhanced basal and/or IFNc-induced S727 phosphorylation, also yielded enhanced IFNcinduced IDO production and in the case of STAT1 overexpression or PTEN inhibitor treatment also enhanced the suppression of Tcell by MSC. However, the possibility that STAT1 or PI3K overexpression or PTEN inhibition may affect MSC function via additional, yet unknown mechanisms cannot be fully excluded.
STAT1 has various downstream targets that are cell type and context dependent. As an example, the IDO promoter includes two IFNc-stimulated response elements and three gamma activated site (GAS) elements that interact with IFNc regulatory factor-1 and STAT1, respectively, the former requiring new protein synthesis that can be regulated by STAT1 [37, 38] . Recently, chromatin immunoprecipitation followed by deep sequencing analysis in HeLa cells revealed 1,441 STAT1 target genes of which 194 were upregulated by IFNc [39] . In the same study, it was shown that, similar to our results on IDO production by CB-MSC, STAT1 binding to GAS alone was insufficient to fully activate target genes, suggesting complexity in STAT1-mediated gene regulatory mechanisms [39] .
Interestingly, however, STAT1 overexpression or PTEN inhibition significantly sensitized CB-MSC to the effects of IFNc and dramatically potentiated IFNc induced IDO production. Consequently, STAT1 overexpressed MSC showed enhanced Tcell suppression. Of note, unstimulated CB-MSC overexpressing STAT1 suppressed T cells as strongly as control CB-MSC that had been prestimulated with an exogenous dose of IFNc. Small amounts of IFNc produced by activated T cells in the Tcell suppression assay apparently sufficed to induce a large amount of IDO production in STAT1 overexpressing CB-MSC (as in Fig. 5A ), an amount usually only seen with additional exogenous IFNc stimulation. This suggests that CB-MSC with STAT1 or PI3K pathway overactivity still undergo physiological regulation by IFNc and do not show unrestrained immunosuppressive activity, a feature that would not be desired in therapeutic application. However, MSCs overexpressing CA-PI3Ka proliferate more than control cells (Supporting Information Fig. S2 ) and many cancers show overactivation of PI3K, suggesting tumorigenic potential of PI3K overexpressing MSC. PTEN inhibitor pretreatment (counter player of PI3K) primed MSC to be more immunosuppressive in the presence of IFNc, similar to CA-PI3Ka overexpression, but did not change proliferation of MSC. PTEN inhibitor was only used to pretreat CB-MSC and was not present during the immunosuppression assay, therefore suggesting that inhibition of this pathway primes CB-MSC toward a stronger immunosuppressive phenotype. PTEN inhibitor pretreatment was also recently shown to augment the efficacy of transfused neutrophils in mouse disease models [40] . It thus appears that this approach could be very interesting for clinical applications, since it does not include any permanent cell modification.
CONCLUSIONS
In summary, our data indicate that an interplay of PI3Ka and STAT1 enhances the MSC2 phenotype and plays a key role in IFNc-mediated IDO induction, providing an opportunity to explore manipulation of the STAT1 and PI3K pathway to enhance immunosuppressive function of CB-MSC for the treatment of various inflammatory disorders in vivo.
